This includes IDH1/2 in gliomas [70] and acute myeloid leukaemia (AML) [79], SDH in PGLs [116] and FH in HLRCC [117] due to the production of oncometabolites, D-2-HG, succinate and fumarate. Here, IDH1 is linked to central nervous system cancer.